AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Connect Biopharma Initiates Coverage at Outperform with $7.50 Price Target
ByAinvest
Tuesday, Jul 22, 2025 9:55 am ET1min read
Northland analyst Carl Byrnes initiates coverage of Connect Biopharma with an Outperform rating and $7.50 price target, citing the lead candidate rademikibart as the first biologic for acute exacerbations in asthma and COPD. Byrnes expects topline data from Phase 2 studies in H1 2026 and sees peak sales potential exceeding $5B.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) has announced plans to terminate its American Depositary Receipt (ADR) program and directly list ordinary shares on the Nasdaq Global Market. The company aims to enhance institutional visibility, minimize depositary fees, and broaden its investor base [1].The termination of the ADR program is scheduled to occur on or about September 2, 2025. Following this termination, ADRs will be mandatorily canceled and exchanged for ordinary shares at a one-for-one ratio. The company plans to list its ordinary shares on Nasdaq under the symbol "CNTB" immediately following the termination [1].
The move is part of Connect Biopharma's strategy to become a U.S.-centric organization and align its stock with the U.S. market. The company believes this shift will improve its visibility among institutional investors and eliminate ADR depositary fees, thereby strengthening its financial position [1].
Northland analyst Carl Byrnes has initiated coverage of Connect Biopharma with an Outperform rating and a $7.50 price target. Byrnes cited the lead candidate rademikibart as the first biologic for acute exacerbations in asthma and COPD. He expects topline data from Phase 2 studies in H1 2026 and sees peak sales potential exceeding $5B [2].
References:
[1] https://www.nasdaq.com/articles/connect-biopharma-terminate-adr-program-and-list-ordinary-shares-nasdaq
[2] https://www.nasdaq.com/articles/northland-analyst-carl-byrnes-initiates-coverage-of-connect-biopharma-with-outperform-rating-and-price-target
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet